Tag: ESC 2017

ESC 2017: Further decreasing mortality after STEMI will be difficult

According to results from the FAST-MI programme, six-month mortality after ST-segment elevation myocardial infarction (STEMI) and after non-STEMI (NSTEMI) considerably decreased between 1995 and...

ESC 2017: Post-TAVI clinical leaflet thrombosis is “infrequently reported” but is...

Of 5,691 adverse events following transcatheter aortic valve implantation (TAVI) that were reported to the FDA’s manufacturer and user facility device experience (MAUDE) database,...

ESC 2017: More evidence that supplemental oxygen in normoxic patients with...

Data from DET02X-AMI (Determination of the role of oxygen in suspected acute myocardial infarction) show that supplemental oxygen in normoxic patients with suspected myocardial...

ESC 2017: Alternative strategies needed for treating stenotic lesions in saphenous...

The recent DIVA (Drug-eluting stents vs. bare metal stents in saphenous vein graft angioplasty) trial, which was presented at the European Society of Cardiology...

ESC 2017: CABG is the “preferred strategy” for multivessel revascularisation in...

Data from a nationwide observational cohort study indicate that coronary artery bypass grafting (CABG) should be used instead of percutaneous coronary intervention (PCI) to...

ESC 2017: Young cardiologists discuss highlights of congress

In this video from the European Society of Cardiology (ESC), Steen Dalby Kristensen (Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark) talks to members...

ESC 2017: MobiusHD implant shown to reduce resistant hypertension

The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate that the device is associated with a reduction in 24-hour ambulatory...

ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...

The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...

ESC 2017: Subanalysis of PEGASUS shows ticagrelor reduces cardiovascular death by...

A new subanalysis from the phase III PEGASUS-TIMI 54 trial, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona,...

ESC 2017: Hexacath’s titanium-nitride-oxide coated stent matches Boston Scientific’s Synergy for...

During a late-breaking science session at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), Pim Tonino (Heart center Catharina Hospital, Eindhoven,...

ESC 2017: Best-practice PCI outperforms conventional PCI in patients with de...

The SYNTAX II study has found that percutaneous coronary intervention (PCI) using state-of-the-art techniques—including physiological assessment and a new-generation drug-eluting stent—significantly reduces the rate...

ESC 2017: SPYRAL HTN-OFF MED provides “proof of principle” that renal...

Results from SPYRAL HTN-OFF MED indicate that renal denervation, compared with a sham procedure, significantly reduces blood pressure in patients with hypertension who are...

ESC 2017: Significantly lower event rates with Orsiro than with Xience

  Results from the BIOFLOW V study indicate that patients who undergo percutaneous coronary intervention (PCI) using a sirolimus-eluting stent with a biodegradable polymer (Orsiro,...

ESC 2017: Case builds for dropping aspirin from triple therapy in...

The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...